One of the key targets that ZEB2/LSD1 directly represses is the pro-apoptotic BCL2L11 (BIM) gene, and consequently confers a selective sensitivity of ETP-ALL to LSD1i in vivo. This evidence concerns the gene BCL2L11 and acute lymphoblastic leukemia.